Needham has initiated coverage on NewAmsterdam Pharma Company N.V (NASDAQ:NAMS), a clinical-stage biopharma developing obicetrapib, an orally-dosed CETP inhibitor for lowering cholesterol. In July, NewAmsterdam Pharma released topline data from the Phase 3 BROOKLYN trial, the first of four studies in NewAmsterdam’s pivotal clinical development program, to evaluate obicetrapib in adult patients with heterozygous familial hypercholesterolemia whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The study achieved the primary endpoint of LS mean r…
